Open to all scientists researching new therapeutics in Cambridge and the local area

The purpose of the CamNTF forum is to promote interactions between scientists from academia & industry in order to improve opportunities for biotechnology research and development. Meeting attendance is free but all attendees must register in advance.

CamNTF was founded in 2015 by Dr David Rees (Astex Pharmaceuticals, CSO) in collaboration with Professor Sir Tom Blundell (University of Cambridge, Sir William Dunn Professor of Biochemistry) and Professor Patrick Maxwell (University of Cambridge, Regius Professor of Physic, Director Cambridge University Health Partners).

The forum was made possible by key scientific sponsors: Professor Michael Wakelam (Babraham Institute, Director), Professor Ewan Birney (EMBL-EBI, Associate Director), Dr Mene Pangalos (AstraZeneca, R&D Director) and Professor Ian Wilkinson (University of Cambridge, Professor of Therapeutics; Director of CUHP’s Office for Translational Research).

The April meeting aims at presenting and discussing cutting-edge science in the area of RNA Therapeutics by academia and industry leaders.

Wednesday 24th April 2024 (17:30 – 20:00)

MRC Toxicology - Seminar Room, Gleeson Building, Tennis Court Road, Cambridge, CB2 1QR.

PLEASE, REGISTER (FREE) TO THE EVENT FOLLOWING THE LINK BELOW. THANK YOU.

https://www.eventbrite.co.uk/e/cambridge-new-therapeutics-forum-camntf-tickets-865424988437

 

Six meeting a year are organised, around Cambridge, hosted by various organisations and covering a wide range of topics all related to new therapeutics.